Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

Patent Docs Highlights the BIO IPDx Symposium

shutterstock_10020697

Patent Docs recently highlighted McDonnell Boehnen Hulbert & Berghoff’s (MBHB) panel at BIO’s IP and Diagnostics Symposium (IPDx).  Moderated by Donald Zuhn at MBHB, panelists from MBHB, Roche Diagnostics, and the USPTO discussed the impact of the Myriad decision on obtaining patent protection for genetic diagnostics.  The panel concluded the following: “While there was agreement that the Myriad holding is not limited to human DNA, there was spirited disagreement regarding its long-term impact on patents claiming naturally Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO IP & Diagnostics Symposium

Final IPDX logo

BIO’s IP & Diagnostics Symposium (BIO IPDX) will review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. The program will also explore some of the potential regulatory dimensions. BIO aims to use this event to inform industry and government alike on how to move the science forward in the current climate. Where & Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Joins Alliance for Fair Trade with India

shutterstock_26191726

BIO recently joined the Alliance for Fair Trade with India along with the U.S. Chamber of Commerce, the National Association of Manufacturers, Solar Energy Industries Association, and others. The new Alliance website states: Over the last year, policymakers and courts in India have engaged in a persistent pattern of discrimination that is hurting a wide range of manufacturing and services industries and jobs in the United States. India has recently mandated domestic content rules that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

MERS, Patents, and Material Transfer Agreements: What WHO Didn’t Know

Photo by NIAID_Flickr

The outbreak of the Middle East Respiratory Syndrome (MERS-CoV), a SARS like virus has lead to some strong anti-IP statements in Geneva.  A recent article titled “Finding a Fall Guy for Middle East Respiratory Syndrome” in IPWatchdog provides context from multiple news sources and concludes: “An independent review of the claims that patents and the [Material Transfer Agreements] are hindering international MERS-COV research appeared in a May 28, 2013 story in Science Insider. Here’s the lead: Are Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Myriad Supreme Court Decision: BIO’s Statement

4973532326_6c75ba32ba copy

Statement On U.S. Supreme Court Review Of Isolated DNA Patents Washington, D.C. (June 13, 2013) Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on  the U.S. Supreme Court’s decision regarding Myriad Genetics’ patent claims on isolated DNA molecules: “The Supreme Court today summarily ruled that so-called cDNA remains eligible for patenting.  cDNA is the commercially most important form of DNA used in biotechnology.  Today’s decision offers urgently-needed Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , ,